The main objective of this Research Program is to define and understand the links between p63, immune signaling, and NF-κB deregulation in CLL. Special focus will be given on the impact of p63 on CLL evolution, including resistance to and/or progression after treatment with both chemoimmunotherapy and signaling inhibitors; as well as Richter’s transformation. It aims at dissecting clinical aggressiveness in CLL and also in identifying optimal combinations of signaling inhibitors for a subgroup of patients with adverse prognosis, thus refining patient management.
